

# Multi-marker Approach Using Procalcitonin, Presepsin, Galectin-3, and Soluble Suppression of Tumorigenicity 2 in Sepsis

Hyeong Nyeon Kim<sup>1</sup>, Hanah Kim<sup>1</sup>, Mina Hur<sup>1</sup>, Hee-Won Moon<sup>1</sup>, Yeo-Min Yun<sup>1</sup>, and Salvatore Di Somma<sup>2</sup>; on behalf of GREAT Network.

<sup>1</sup>Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea

<sup>2</sup>Departments of Medical-Surgery Sciences and Translational Medicine, School of Medicine and Psychology, 'Sapienza' University, Sant' Andrea Hospital, Rome, Italy

## Background

- Timely diagnosis and risk stratification in sepsis are important to make appropriate and prompt treatment decisions.
- We investigated the prognostic utilities of emerging biomarkers in septic patients.

## Material & Methods

- In a total of 157 septic patients (112 patients with sepsis; 45 patients with septic shock), procalcitonin (PCT), presepsin, galectin-3, and soluble suppression of tumorigenicity 2 (sST2) were measured (Table 1).
- The assay results were analyzed in relation to sepsis severity and 30-day mortality.

**Table 1.** Characteristics of study population

Variable	All patients (N = 157)
Sepsis criteria, n (%)	157 (100.0)
Sepsis, n (%)	112 (71.3)
Septic shock, n (%)	45 (28.7)
Patients enrollment	
Intensive care unit, n (%)	94 (59.9)
Emergency room, n (%)	63 (40.1)
Age (years), median [IQR]	70 [57.7 – 77.0]
Males, n (%)	95 (60.5)
Hospital stay (days), median [IQR]	16 [8 – 40]
In-hospital mortality, n (%)	40 (25.5)
30-day mortality, n (%)	34 (21.7)
Co-morbidities	
Hemato-oncologic, n (%)	31 (19.6)
Pulmonary, n (%)	29 (18.6)
Cerebrovascular, n (%)	28 (17.5)
Renal and genitourinary, n (%)	19 (12.4)
Gastrointestinal, n (%)	18 (11.3)
Cardiovascular, n (%)	16 (10.3)
Others, n (%)	16 (10.3)
eGFR by MDRD Study equation (mL/min/1.73 m <sup>2</sup> ), median [IQR]	44.45 [20.83 – 81.33]
SOFA score range	2 – 11
	2 (45, 28.7%); 3 (32, 20.4%); 4 (26, 16.6%); 5 (14, 8.9%); 6 (13, 8.3%); 7 (12, 7.6%); 8 (6, 3.8%); 9 (3, 1.9%); 10 (3, 1.9%); 11 (3, 1.9%)
CRP (mg/dL), median [IQR]	12.54 [7.22 – 22.0]
WBC (x 10 <sup>9</sup> /L), median [IQR]	12.47 [8.18 – 17.10]
PCT (ng/mL), median [IQR]	6.19 [2.25 – 21.99]
Presepsin (pg/mL), median [IQR]	2,714.0 [1,479.3 – 4,129.7]
Galectin-3 (ng/mL), median [IQR]	30.8 [17.9 – 58.5]
sST2 (ng/mL), median [IQR]	214.5 [133.6 – 238.8]


## Results

- PCT, presepsin, galectin-3, and sST2 increased significantly according to the sepsis severity (all  $P < 0.01$ ) (Table 2).
- PCT, presepsin, galectin-3, and sST2 were all comparable for the prediction of septic shock (Fig. 1).
- Galectin-3 was a risk predictor for 30-day mortality (hazard ratio [HR] = 11.03, 95% confidence interval [CI] = 2.69 - 45.25) (Table 3).
- The risk of 30-day mortality increased stepwise as the number of biomarkers above cut-offs increased, and the highest risk was observed when all four biomarkers increased (HR = 3.3, 95% CI = 1.3 - 8.5).

**Table 2.** Comparison of PCT, presepsin, galectin-3, and sST2 between sepsis and septic shock

	Sepsis (N = 112)	Septic shock (N = 45)	P*
Procalcitonin (ng/mL)	5.35 (1.52 – 14.00)	9.73 (4.03 – 35.13)	0.0053
Presepsin (pg/mL)	2,159.5 (1357.5 – 3743.5)	3,679.0 (2738.8 – 6335.5)	< 0.0001
Galectin-3 (ng/mL)	24.4 (15.3 – 54.6)	49.6 (29.4 – 81.3)	< 0.0001
sST2 (ng/mL)	205.4 (103.1 – 233.9)	237.3 (215.1 – 254.6)	< 0.0001

Data are expressed as median (interquartile range). \*Mann-Whitney U test.




**Figure 1.** Comparison of the receiver operating characteristics curves to predict septic shock and 30-day mortality.

**Table 3.** Comparison of PCT, presepsin, galectin-3, and sST2 according to the 30-day mortality

	Total (N = 157)		P*	30-day mortality	
	Survivor (N = 123)	Non-survivor (N = 34)		HR (95% CI)	P†
Procalcitonin (ng/mL)	6.19 (2.24 – 22.39)	6.61 (2.22 – 20.78)	NS	0.60 (0.33 – 1.08)	NS
Presepsin (pg/mL)	2,310.0 (1,375.8 – 3,920.2)	3,549.0 (2,493.7 – 8,242.7)	0.0011	2.25 (0.74 – 6.85)	NS
Galectin-3 (ng/mL)	24.5 (16.7 – 47.5)	58.6 (37.0 – 82.2)	< 0.0001	11.03 (2.69 – 45.25)	0.0009
sST2 (ng/mL)	209.5 (116.9 – 236.9)	237.3 (208.8 – 253.3)	0.0020	14.91 (0.93 – 240.4)	NS

Data are expressed as median (interquartile range). \*Mann-Whitney U test. †Cox proportional-hazard regression using log-transformation of variables. Abbreviations: NS, not significant



Group	1	2	3	4	5
0	-	-	-	-	-
1	-	1.5 (0.5 – 4.4)	2.4 (0.9 – 6.6)	6.2 (2.1 – 17.9)	14.5 (3.2 – 64.7)
2	-	-	1.6 (0.6 – 4.4)	4.1 (1.4 – 11.8)	9.6 (2.1 – 42.8)
3	-	-	-	2.6 (0.9 – 7.1)	6.1 (1.4 – 26.0)
4	-	-	-	-	2.3 (0.5 – 10.4)

**Figure 2.** Risk prediction by multimarker-approach using below/above cut-offs of PCT, presepsin, galectin-3, and sST2.

## Conclusions

This is the first study that demonstrated the utility of PCT, presepsin, galectin-3, and sST2, as a single measurement or combination, for the prediction of disease severity and clinical outcome in sepsis. Multi-marker approach would be beneficial for the appropriate management of septic patients.

Abbreviations: IQR, interquartile range; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; SOFA, sequential organ failure assessment; PCT, procalcitonin; sST2, soluble suppression of tumorigenicity 2.

Contact address:

Hyeong Nyeon Kim, [dockylekim@gmail.com](mailto:dockylekim@gmail.com)

Mina Hur, [dearmina@hanmail.net](mailto:dearmina@hanmail.net)

